97 completed, 13 unknown, 9 recruiting, 5 not yet recruiting. 79 Phase 1, 21 Phase 2, 20 Phase 3, 10 Phase 4, 4 Not applicable.
Follow Rifampicin: new trials by email Literature Review of Rifampicin trials Research Report on Rifampicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080 HRS-8080, Rifampicin - Breast Cancer | Phase 1 | Not yet recruiting | Shandong Suncadia Medicine Co., Ltd. | 18 | 2026-11-01 | 2026-10-15 |
| Re-evaluating the Duration in Children of TB Treatment Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 230 | 2026-10-01 | 2026-09-29 |
| A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults Itraconazole, Rifampicin, Omeprazole - Healthy Subjects | Phase 1 | Not yet recruiting | InventisBio Co., Ltd | 60 | 2026-09-16 | 2026-10-15 |
| Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction QLC5508 (Investigational Product / Formulation T), QLC5508 (Reference Product / Formulation R), Itraconazole - Refractory or Relapsed Solid Tumors | Phase 1 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 48 | 2026-06-09 | 2026-09-15 |
| Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects Methotrexate, Rifampicin, Cyclosporine - Drug Drug Interaction (DDI) | Phase 1 | Active not recruiting | Seoul National University Bundang Hospital | 12 | 2025-05-14 | 2025-09-29 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 315 | 2025-03-11 | 2026-10-19 |
| 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam Isoniazid, Rifapentine, Rifampicin - Tuberculosis Infection | Phase 3 | Withdrawn | Freundeskreis Für Internationale Tuberkulosehilfe e.V | 2024-11-01 | 2026-09-09 | |
| An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM Rifampicin, Azithromycin, Isoniazid - Severe Acute Malnutrition, HIV | Phase 3 | Completed | Queen Mary University of London | 674 | 2024-07-15 | 2026-08-25 |
| A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers Ensartinib, Rifampicin, Itraconazole - Healthy | Phase 1 | Unknown | Betta Pharmaceuticals Co., Ltd. | 36 | 2024-07-01 | 2024-07-09 |
| Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects Itraconazole, Rifampicin - NSCLC | Phase 1 | Completed | TYK Medicines, Inc | 48 | 2024-03-12 | 2024-12-30 |
| Intensified Short Course Regimen for TBM in Adults High dose rifampicin (25mg/kg), Moxifloxacin 400mg, Aspirin 150 mg - Tuberculous Meningitis | Phase 3 | Not yet recruiting | Indian Council of Medical Research | 372 | 2024-03-01 | 2023-12-21 |
| Drug Interaction Study Itraconazole, rifampicin, Ecopipam - Drug Interaction | Phase 1 | Completed | Emalex Biosciences Inc. | 45 | 2024-01-18 | 2024-09-19 |
| Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD) - Tuberculous Meningitis | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 330 | 2023-12-07 | 2026-06-02 |
| Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride rifampicin, Fluconazole, Omeprazole - Interaction Drug Food | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 68 | 2023-12-04 | 2025-02-14 |
| Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement Chlorhexidine, Gentamicin, Rifampin - Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation | Phase 3 | Active not recruiting | Rush University Medical Center | 200 | 2023-12-04 | 2026-07-24 |
| A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects JAB-21822, Itraconazole, Omeprazole - Healthy Subjects | Phase 1 | Completed | Allist Pharmaceuticals, Inc. | 66 | 2023-11-25 | 2025-04-04 |
| A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Methotrexate in Elderly Subjects Methotrexate Sodium, Rifampicin - Drug Interactions | Phase 1 | Unknown | Seoul National University Bundang Hospital | 10 | 2023-08-21 | 2023-10-31 |
| Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin rifampicin - Pediatric HIV Infection, Tuberculosis Infection | Phase 1 | Recruiting | Brigham and Women's Hospital | 20 | 2023-07-07 | 2026-07-30 |
| Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects HLX208, Itraconazole 200 mg, Rifampicin - NSCLC | Phase 1 | Completed | Shanghai Henlius Biotech | 20 | 2023-07-04 | 2024-04-05 |
| PanACEA - STEP2C -01 BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Recruiting | Michael Hoelscher | 390 | 2023-04-14 | 2025-10-07 |
Showing 20 of 135. Sign in to see all of them.
Tuberculosis (26) · Tuberculosis, Pulmonary (20) · Neoplasms (4) · HIV Infections (3) · Lymphoma, Non-Hodgkin (3) · Tuberculosis, Meningeal (3) · Alzheimer Disease (2) · Erectile Dysfunction (2) · Inflammation (2) · Latent Tuberculosis (2) · Renal Insufficiency, Chronic (2) · Acquired Immunodeficiency Syndrome (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Arthritis, Rheumatoid (1) · Atypical Hemolytic Uremic Syndrome (1)
Boehringer Ingelheim (9) · AstraZeneca (7) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · National University Hospital, Singapore (5) · Seoul National University Hospital (4) · University of Oulu (4) · Bayer (3) · Hoffmann-La Roche (3) · Jiangsu HengRui Medicine Co., Ltd. (3) · Michael Hoelscher (3) · Beijing Chest Hospital (2) · Global Alliance for TB Drug Development (2) · Hadassah Medical Organization (2) · Janssen Research & Development, LLC (2) · Pfizer (2)
China (22) · United States (19) · South Africa (16) · Germany (11) · Netherlands (8) · South Korea (8) · United Kingdom (8) · France (7) · India (7) · Uganda (7) · Philippines (6) · Singapore (6) · Spain (6) · Finland (5) · Tanzania (5)
Nicholas Paton (6) · Janne Hukkanen, MD, PhD (4) · Andreas Diacon, MD (2) · Michael Hoelscher, MD (2) · Rodney Dawson, MD (2) · Wei Zhao, Doctor (2) · A-Dong Shen, Master (1)
PMID 35229613, PMID 41744113, PMID 10798549, PMID 11448564, PMID 14557966, PMID 16470119, PMID 16988514, PMID 17192170, PMID 18366444, PMID 18795962, PMID 18989231, PMID 19146007, PMID 20002783, PMID 20632458, PMID 21283017, PMID 21410904, PMID 21453653, PMID 22083071, PMID 22129166, PMID 2246576, PMID 22534255, PMID 23305215, PMID 23392467, PMID 23616495, PMID 24491572, PMID 24507091, PMID 25162818, PMID 25209610, PMID 25261418, PMID 25261424, PMID 25407158, PMID 25512422, PMID 25654354, PMID 25950206, PMID 25959631, PMID 26202768, PMID 26339415, PMID 26918544, PMID 27317471, PMID 27540363, PMID 27745744, PMID 28100438, PMID 28333342, PMID 28399802, PMID 28629333, PMID 28715853, PMID 29369162, PMID 29381826, PMID 29500603, PMID 29507938
2018 (5), 2016 (4), 2014 (2), 2019 (2), 2009 (1), 2015 (1), 2017 (1), P01NS044233 (1), R01DK112955 (1), U01AI068636 (1), U01AI134585 (1), U01AI192041 (1), U54NS065736 (1)